The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:

Vaccines and therapeutics in development
Diagnostics with U.S. FDA emergency use authorization
Clinical trials of biopharma products affected by COVID-19

A preview of the next edition of BioWorld, June 16, 2025

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biocryst, Merck, Moderna, Sumitomo, Urogen, Xediton.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astrazeneca, Cspc, Incyte, Specialised.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astria, Beam, Bioarctic, Biorestorative, Celldex, Enliven, Incyte, Johnson& Johnson, Kancera, Keymed, Silence.

Biopharmas raising money in public or private financings, including: Centivax, Enliven, Indaptus, Parallel Bio, Quince, Rebel.

New hires and promotions in the biopharma industry, including: Courage, Ionis, Tonix.

The top 10 biopharma stock gainers and losers for the week.

A quick look back at top stories.